- Home
- AHG vs CMPX Comparison
AHG vs CMPX Comparison
Compare AHG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- CMPX
- Stock Information
- Founded
- AHG 2013
- CMPX 2014
- Country
- AHG China
- CMPX United States
- Employees
- AHG N/A
- CMPX N/A
- Industry
- AHG Business Services
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- CMPX Health Care
- Exchange
- AHG Nasdaq
- CMPX Nasdaq
- Market Cap
- AHG 752.4M
- CMPX 752.4M
- IPO Year
- AHG N/A
- CMPX N/A
- Fundamental
- Price
- AHG $1.51
- CMPX $4.98
- Analyst Decision
- AHG
- CMPX Strong Buy
- Analyst Count
- AHG 0
- CMPX 7
- Target Price
- AHG N/A
- CMPX $14.43
- AVG Volume (30 Days)
- AHG 10.4K
- CMPX 1.9M
- Earning Date
- AHG 12-15-2025
- CMPX 11-05-2025
- Dividend Yield
- AHG N/A
- CMPX N/A
- EPS Growth
- AHG N/A
- CMPX N/A
- EPS
- AHG N/A
- CMPX N/A
- Revenue
- AHG $14,777,798.00
- CMPX N/A
- Revenue This Year
- AHG N/A
- CMPX N/A
- Revenue Next Year
- AHG N/A
- CMPX N/A
- P/E Ratio
- AHG N/A
- CMPX N/A
- Revenue Growth
- AHG 512.09
- CMPX N/A
- 52 Week Low
- AHG $0.74
- CMPX $1.33
- 52 Week High
- AHG $2.35
- CMPX $5.16
- Technical
- Relative Strength Index (RSI)
- AHG 45.04
- CMPX 69.23
- Support Level
- AHG $1.33
- CMPX $4.79
- Resistance Level
- AHG $1.56
- CMPX $5.11
- Average True Range (ATR)
- AHG 0.09
- CMPX 0.32
- MACD
- AHG 0.00
- CMPX 0.04
- Stochastic Oscillator
- AHG 35.94
- CMPX 89.12
About AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.